Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Verve Therapeutics, Inc. (VERV) had Normalized Income after Taxes of $-50.03M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
$13.08M |
|
$-50.03M |
|
-- |
|
$13.08M |
|
$69.15M |
|
$-56.07M |
|
$6.11M |
|
$-49.96M |
|
$-49.96M |
|
$-50.03M |
|
$-50.03M |
|
$-50.03M |
|
|
Normalized Income after Taxes |
$-50.03M |
$-56.07M |
|
$-56.52M |
|
84.72M |
|
84.72M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$542.75M |
|
$18.64M |
|
$104.64M |
|
$647.39M |
|
$42.91M |
|
-- |
|
$111.08M |
|
$153.99M |
|
$493.40M |
|
$493.40M |
|
$493.40M |
|
88.76M |
|
| Cash Flow Statement Financials | |
$-157.69M |
|
$74.88M |
|
$49.20M |
|
$210.95M |
|
$177.33M |
|
$-33.62M |
|
$43.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-428.65% |
|
-428.65% |
|
-- |
|
-381.97% |
|
-382.53% |
|
$-161.43M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
4.02 |
|
22.40 |
|
-10.14% |
|
-10.14% |
|
-7.73% |
|
-10.14% |
|
$5.56 |
|
$-1.91 |
|
$-1.86 |
|